Megan Othus

67PUBLICATIONS
227CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)HaematologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (67)

|Jul 13, 2026
Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

|Jun 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

|Jun 08, 2026
Cancer Chemoimmunotherapy: Time Will Tell.

|Jun 01, 2026
Astatine 211-based conditioning with a humanized CD45 antibody for autologous hematopoietic stem cell gene therapy.

|Apr 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results.

|Mar 12, 2026
Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609).

Young Kwang Chae, Megan Othus, Jiyon Lyu

Pageof 12

Frequent Collaborators

26 joint publications

Roland Walter

9 joint publications

Young Kwang Chae

9 joint publications

Brenda Sandmaier

8 joint publications

Razelle Kurzrock